Home
>
US Stocks
>
JANUX THERAPEUTICS INC

JANUX THERAPEUTICS INC (JANX)

$11.59

+0.21

(+1.8%)▲

Live

Insights on JANUX THERAPEUTICS INC

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 2.84M → 2.04M (in $), with an average decrease of 28.0% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -16.06M → -17.45M (in $), with an average decrease of 8.7% per quarter

  • Vs SGEN

    In the last 1 year, Seagen Inc has given 36.8% return, outperforming this stock by 39.7%

Performance

  • $11.25
    $11.64
    $11.59
    downward going graph

    2.93%

    Downside

    Day's Volatility :3.35%

    Upside

    0.43%

    downward going graph
  • $9.40
    $23.64
    $11.59
    downward going graph

    18.9%

    Downside

    52 Weeks Volatility :60.24%

    Upside

    50.97%

    downward going graph

Returns

PeriodJANUX THERAPEUTICS INCSector (Health Care)Index (Russel 2000)
3 Months
-31.54%
0.3%
-6.7%
6 Months
-16.53%
-8.3%
-6.2%
1 Year
2.29%
-4.8%
-6.3%
3 Years
-59.03%
23.8%
26.9%

Highlights

Market Capitalization
476.3M
Book Value
$7.45
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-1.44
Wall Street Target Price
27.5
Profit Margin
0.0%
Operating Margin TTM
-813.91%
Return On Assets TTM
-12.79%
Return On Equity TTM
-20.11%
Revenue TTM
9.1M
Revenue Per Share TTM
0.22
Quarterly Revenue Growth YOY
28.9%
Gross Profit TTM
-44.8M
EBITDA
-72.6M
Diluted Eps TTM
-1.44
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.99
EPS Estimate Next Year
-2.48
EPS Estimate Current Quarter
-0.49
EPS Estimate Next Quarter
-0.52

Analyst Recommendation

Buy
    91%Buy
    8%Hold
    0
    0%Sell
Based on 12 Wall street analysts offering stock ratings for JANUX THERAPEUTICS INC(by analysts ranked 0 to 5 stars)
Based on 12 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
11
10
10
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 137.27%

Current $11.59
Target $27.50

Technicals Summary

Sell

Neutral

Buy

JANUX THERAPEUTICS INC is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
JANUX THERAPEUTICS INC
JANUX THERAPEUTICS INC
-25.83%
-16.53%
2.29%
-59.03%
-59.03%
Moderna, Inc.
Moderna, Inc.
-5.37%
-28.24%
-13.14%
103.02%
578.71%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-10.12%
-3.55%
9.07%
20.95%
140.97%
Seagen, Inc.
Seagen, Inc.
-2.85%
59.4%
42.61%
21.68%
240.77%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-4.35%
4.3%
22.83%
15.12%
110.67%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
JANUX THERAPEUTICS INC
JANUX THERAPEUTICS INC
NA
NA
NA
-1.99
-0.2
-0.13
0.0
7.45
Moderna, Inc.
Moderna, Inc.
11.22
11.22
0.0
-1.83
0.27
0.12
0.0
49.12
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
19.72
19.72
9.01
41.59
0.19
0.1
0.0
219.38
Seagen, Inc.
Seagen, Inc.
NA
NA
18.53
-2.88
-0.23
-0.12
0.0
14.54
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
26.53
26.53
0.41
13.64
0.26
0.17
0.0
56.05
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
JANUX THERAPEUTICS INC
JANUX THERAPEUTICS INC
Buy
$476.3M
-59.03%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$48.1B
578.71%
11.22
31.77%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$79.5B
140.97%
19.72
33.81%
Seagen, Inc.
Seagen, Inc.
Hold
$36.3B
240.77%
NA
-31.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$85.0B
110.67%
26.53
35.4%

Institutional Holdings

  • RA Capital Management, LLC

    20.73%

  • FMR Inc

    13.40%

  • EcoR1 Capital, LLC

    9.18%

  • Orbimed Advisors, LLC

    6.78%

  • HHG PLC

    4.47%

  • Citadel Advisors Llc

    4.43%

Corporate Announcements

  • JANUX THERAPEUTICS INC Earnings

    JANUX THERAPEUTICS INC’s price-to-earnings ratio stands at None

    Read More

Company Information

Janux Therapeutics is developing safe, effective novel immunotherapies with the company’s proprietary TRACTr technology. Janux’s TRACTr technology employs a modular design to rapidly engineer drug candidates against specific targets. The Janux TRACTr development pipeline targets multiple solid tumor indications, including colorectal, gastroesophageal, prostrate, NSCLC, triple negative breast, and ovarian cancers. Janux technology can be applied to immunotherapies that target all three stages of an anti-tumor immune response. Combining Janux’s tumor-specific activation with multi-stage anti-tumor signaling has the potential to significantly improve safety, expand the therapeutic dosing window, and maximize patient responses. Janux was founded in the Avalon Ventures accelerator, COI Pharmaceuticals, Inc., in San Diego.

Organization
JANUX THERAPEUTICS INC
Employees
62
CEO
Dr. David Alan Campbell Ph.D.
Industry
Healthcare

Discover More

FAQs